Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest From Harris FRC

UCB Links With Daiichi Sankyo For Epilepsy In Japan

UCB has chosen Daiichi Sankyo as its new commercial partner in Japan for an epilepsy drug, building on an existing relationship in the allergy area.

BioPharmaceutical Japan

UCB, Others Sue 15 Generics Makers For Violating Vimpat Drug Patent

Glenmark, Ranbaxy Laboratories, Sun Pharma and other India drug makers are among 15 sued in a U.S. federal court for violating the patent of the epilepsy drug Vimpat (lacosamide) licensed to UCB.

BioPharmaceutical India

Schwarz Shops Fesoterodine to Pfizer

Pfizer Inc.'s acquisition of worldwide rights to Schwarz's registration-stage incontinence product fesoterodine for $210 million plus royalties is the most recent milestone in the German company's successful integration of drug development to its legacy marketing organization-and one that nearly guarantees it a substantial revenue stream regardless of how fesoterodine fares in the marketplace.

BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology